1. Monoclonal antibodies point to Achilles’ heel in picornavirus capsid
- Author
-
Mihnea Bostina
- Subjects
0301 basic medicine ,Picornavirus ,Physiology ,viruses ,Picornaviridae ,Biochemistry ,Neutralization ,Viral Packaging ,0302 clinical medicine ,Immune Physiology ,Electron Microscopy ,Enzyme-Linked Immunoassays ,Biology (General) ,Pathology and laboratory medicine ,Microscopy ,Immune System Proteins ,Antimicrobials ,General Neuroscience ,virus diseases ,Antibodies, Monoclonal ,Drugs ,Hepatitis A ,Medical microbiology ,Antivirals ,Capsid ,Viruses ,Monoclonal ,Pathogens ,Antibody ,General Agricultural and Biological Sciences ,Research Article ,QH301-705.5 ,medicine.drug_class ,Immunology ,Biology ,Research and Analysis Methods ,Monoclonal antibody ,Microbiology ,Antibodies ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Virology ,Microbial Control ,medicine ,Animals ,Antigens ,Immunoassays ,Medicine and health sciences ,Pharmacology ,Biology and life sciences ,General Immunology and Microbiology ,Cryoelectron Microscopy ,Viral pathogens ,Organisms ,Proteins ,Electron Cryo-Microscopy ,biology.organism_classification ,medicine.disease ,Hepatitis viruses ,Viral Replication ,Microbial pathogens ,Monoclonal Antibodies ,030104 developmental biology ,Immunologic Techniques ,biology.protein ,Hepatitis A virus ,030217 neurology & neurosurgery - Abstract
Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies—F4, F6, F7, and F9—are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 μM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development., Structures of hepatitis A virus in complex with five neutralizing antibodies reveal a single conserved antigenic site and pinpoint key structure-activity correlates, allowing in silico screening to identify a potent candidate inhibitor drug, golvatinib., Author summary Hepatitis A virus (HAV) is a unique, hepatotropic human picornavirus that infects approximately 1.5 million people annually and continues to cause mortality despite a successful vaccine. There are no licensed therapeutic drugs to date. Better knowledge of HAV antigenic features and neutralizing mechanisms will facilitate the development of HAV-targeting antiviral drugs. In this study, we report 4 potent HAV-specific neutralizing monoclonal antibodies (NAbs), together with our previous reported R10, that efficiently inhibit HAV infection by blocking attachment to the host cell. All 5 epitopes are located within the same patch and are highly conserved across 6 genotypes of human HAV, which suggests a single antigenic site for HAV, highlighting a prime target for structure-based drug design. Analysis of complexes with the 5 NAbs with varying neutralizing activities pinpointed key structure-activity correlates. By using a robust in silico docking method, one promising inhibitor named golvatinib was successfully identified from the DrugBank Database. In vitro assays confirmed its ability to block viral infection and revealed its neutralizing mechanism. Our approach could be useful in the design of effective drugs for picornavirus infections.
- Published
- 2019